Q-omics provides the consensus-scored DEFB131A profile across patient tissues and cancer cell-line models. DEFB131A expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, DEFB131A is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, DEFB131A RNA expression shows 10,935 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, THCA, and THYM as cancer lineages where DEFB131A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB131A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB131A survival associations across molecular data types. DEFB131A RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB131A RNA expression–survival associations across cancer types. High DEFB131A expression shows unfavorable associations in SKCM, KIRC, PCPG, BRCA and BLCA, but favorable associations in STAD. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for DEFB131A RNA expression.
This table summarizes DEFB131A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB131A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB131A shows lower tumor expression in THCA, PRAD, STAD and BRCA. The THCA box plot shows higher DEFB131A RNA expression in normal versus tumor tissue (log2 FC = −1.359, t-test p < 0.001).
This table shows molecular features associated with DEFB131A in patient tissues and cancer cell lines. In patient samples, DEFB131A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB131A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE.
